ProFunds Biotechnology UltraSector Fund Service Class (BIPSX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) with AI Score 47/100 (Weak). ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is a non-diversified fund seeking daily returns consistent with its investment objective, focusing on the biotechnology sector of the U. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 17, 2026ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) Financial Services Profile
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is a non-diversified fund targeting daily investment returns aligned with the biotechnology sector's performance in the U.S. equity market. With a beta of 1.99, it offers high sensitivity to biotech market fluctuations, appealing to investors seeking leveraged exposure.
Investment Thesis
BIPSX presents a high-risk, high-reward investment opportunity for investors with a short-term outlook on the biotechnology sector. With a beta of 1.99, the fund's returns are nearly twice as volatile as the broader market, offering the potential for significant gains but also substantial losses. The fund's non-diversified nature concentrates risk within the biotechnology industry, making it highly sensitive to sector-specific news and events. Key value drivers include positive clinical trial results, regulatory approvals, and advancements in biotechnology innovation. Growth catalysts involve increased investment in healthcare, aging populations, and rising demand for novel therapies. However, potential risks include regulatory setbacks, patent expirations, and competitive pressures from other biotechnology companies. Investors should carefully consider their risk tolerance and investment horizon before investing in BIPSX.
Based on FMP financials and quantitative analysis
Key Highlights
- BIPSX is a non-diversified fund, concentrating its investments in the biotechnology sector.
- The fund aims to provide daily returns consistent with its investment objective.
- The fund's beta is 1.99, indicating high volatility relative to the broader market.
- BIPSX has a market capitalization of $0.14 billion.
- The fund does not offer a dividend yield.
Competitors & Peers
Strengths
- Leveraged exposure to the biotechnology sector.
- Potential for high returns in a short period.
- Daily rebalancing to maintain target leverage.
- Clear and focused investment objective.
Weaknesses
- High volatility and risk of significant losses.
- Non-diversified nature concentrates risk within the biotechnology sector.
- Performance is highly sensitive to sector-specific news and events.
- Leverage can amplify losses.
Catalysts
- Upcoming: Clinical trial results for key biotechnology companies in the fund's portfolio.
- Ongoing: Regulatory decisions on new drug applications.
- Ongoing: Mergers and acquisitions activity in the biotechnology sector.
- Ongoing: Advancements in genomics and personalized medicine.
Risks
- Potential: Regulatory setbacks and clinical trial failures.
- Potential: Patent expirations and generic competition.
- Ongoing: Economic downturns and market volatility.
- Ongoing: Changes in healthcare policies and reimbursement rates.
- Ongoing: High volatility due to the fund's leveraged nature.
Growth Opportunities
- Increased Healthcare Spending: The global healthcare expenditure is projected to reach $10 trillion by 2022, driven by aging populations and rising demand for advanced medical treatments. BIPSX can capitalize on this trend by investing in biotechnology companies developing innovative therapies and diagnostic tools. Timeline: Ongoing, Market Size: $10 Trillion.
- Advancements in Genomics: The rapid advancements in genomics and personalized medicine are creating new opportunities for biotechnology companies. BIPSX can benefit from investing in companies focused on gene editing, gene therapy, and precision diagnostics. Timeline: Ongoing, Market Size: Expanding.
- Regulatory Approvals: The approval of new drugs and therapies by regulatory agencies such as the FDA can significantly boost the stock prices of biotechnology companies. BIPSX can strategically invest in companies with promising drug candidates in late-stage clinical trials. Timeline: Ongoing, Market Size: Varies by drug.
- Mergers and Acquisitions: The biotechnology industry is characterized by frequent mergers and acquisitions, as larger pharmaceutical companies acquire smaller biotechnology companies with promising drug pipelines. BIPSX can benefit from investing in potential acquisition targets. Timeline: Ongoing, Market Size: Varies by deal.
- Emerging Markets Growth: The increasing healthcare spending in emerging markets such as China and India presents a significant growth opportunity for biotechnology companies. BIPSX can invest in companies expanding their operations in these markets. Timeline: Ongoing, Market Size: Expanding.
Opportunities
- Advancements in biotechnology and healthcare innovation.
- Regulatory approvals of new drugs and therapies.
- Increased healthcare spending in emerging markets.
- Mergers and acquisitions in the biotechnology industry.
Threats
- Regulatory setbacks and clinical trial failures.
- Patent expirations and generic competition.
- Economic downturns and market volatility.
- Changes in healthcare policies and reimbursement rates.
Competitive Advantages
- Specialized Focus: BIPSX's focus on the biotechnology sector provides investors with targeted exposure to this industry.
- Leveraged Returns: The fund's leveraged nature offers the potential for amplified returns.
- Daily Rebalancing: The fund's daily rebalancing strategy aims to maintain its target leverage ratio.
About BIPSX
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is designed to provide investors with leveraged exposure to the biotechnology sector within the U.S. equity market. As a non-diversified fund, BIPSX concentrates its investments in a specific segment, aiming to deliver daily returns that correspond to its investment objective. The fund achieves this by strategically employing various financial instruments, carefully selected by the adviser to collectively mirror the desired performance. BIPSX's focus on the biotechnology sector makes it particularly sensitive to developments in pharmaceuticals, genomics, and healthcare innovation. The fund's performance is closely tied to the performance of companies involved in research, development, manufacturing, and marketing of biotechnological products and services. Given its leveraged nature and sector concentration, BIPSX is suitable for investors with a high-risk tolerance and a specific view on the short-term prospects of the biotechnology industry. The fund's investment strategy does not involve diversification across different sectors, which can lead to higher volatility compared to more broadly diversified investment products. The fund was created to give investors a way to amplify their returns based on the biotechnology sector.
What They Do
- Invests in financial instruments to achieve its investment objective.
- Targets daily returns consistent with its investment objective.
- Focuses on the biotechnology sector of the U.S. equity market.
- Provides leveraged exposure to the biotechnology sector.
- Offers investors a way to amplify their returns based on the biotechnology sector.
- Operates as a non-diversified fund.
Business Model
- Generates revenue through management fees charged to investors.
- Aims to provide daily returns consistent with the performance of the biotechnology sector.
- Utilizes financial instruments to achieve its investment objective.
Industry Context
BIPSX operates within the asset management industry, specifically focusing on providing leveraged exposure to the biotechnology sector. The biotechnology industry is characterized by high growth potential driven by innovation in healthcare and pharmaceuticals. However, it is also subject to significant regulatory and clinical trial risks. BIPSX competes with other sector-specific funds and ETFs that offer exposure to the biotechnology industry. The fund's high beta reflects the inherent volatility of the biotechnology sector and the leveraged nature of its investment strategy.
Key Customers
- Individual investors seeking leveraged exposure to the biotechnology sector.
- Institutional investors looking for short-term trading opportunities in the biotechnology market.
- High-risk tolerance investors willing to accept significant volatility.
Financials
Chart & Info
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) stock price: Price data unavailable
Latest News
-
Is ProFunds Biotech Ultra Sector Investor (BIPIX) a Strong Mutual Fund Pick Right Now?
Yahoo! Finance: BIPSX News · Mar 10, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIPSX.
Price Targets
Wall Street price target analysis for BIPSX.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIPSX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
BIPSX Financial Services Stock FAQ
What does ProFunds Biotechnology UltraSector Fund Service Class do?
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is a specialized investment fund designed to provide leveraged exposure to the biotechnology sector within the U.S. equity market. The fund aims to deliver daily returns that correspond to its investment objective by strategically employing various financial instruments. As a non-diversified fund, BIPSX concentrates its investments in a specific segment, making it particularly sensitive to developments in pharmaceuticals, genomics, and healthcare innovation. This fund is tailored for investors with a high-risk tolerance and a specific view on the short-term prospects of the biotechnology industry.
What do analysts say about BIPSX stock?
AI analysis is pending for BIPSX, so there is no current analyst consensus available. However, given its nature as a leveraged sector fund, potential investors may want to evaluate its high beta of 1.99, indicating significant volatility. The fund's performance is closely tied to the biotechnology sector, making it sensitive to regulatory changes, clinical trial outcomes, and market sentiment. Investors should carefully evaluate their risk tolerance and investment horizon before considering BIPSX.
What are the main risks for BIPSX?
The primary risks associated with BIPSX stem from its leveraged nature and concentration in the biotechnology sector. The fund's high beta of 1.99 indicates significant volatility, meaning that it is prone to substantial price swings. Additionally, the biotechnology sector is subject to regulatory risks, clinical trial failures, and patent expirations, which can negatively impact the fund's performance. The fund's non-diversified nature further amplifies these risks, as it is heavily reliant on the performance of a single sector. Investors should be prepared for potentially large losses when investing in BIPSX.
How does ProFunds Biotechnology UltraSector Fund Service Class generate revenue?
ProFunds Biotechnology UltraSector Fund Service Class generates revenue primarily through management fees charged to investors. These fees are typically calculated as a percentage of the fund's assets under management (AUM). The fund's ability to attract and retain investors, as well as its performance relative to its benchmark, directly impacts its AUM and, consequently, its revenue. The fund does not generate revenue through interest income or lending activities, as it is not a lending institution. Instead, its revenue is solely dependent on its ability to manage assets effectively and attract investor capital.
How sensitive is BIPSX to changes in biotechnology sector sentiment?
BIPSX is highly sensitive to changes in biotechnology sector sentiment due to its concentrated investment strategy. The fund's performance is directly tied to the performance of biotechnology companies, making it vulnerable to news and events that impact the sector as a whole. Positive developments, such as successful clinical trial results or regulatory approvals, can lead to significant gains for the fund. Conversely, negative news, such as clinical trial failures or regulatory setbacks, can result in substantial losses. Investors should closely monitor biotechnology sector news and be prepared for potentially volatile price swings in BIPSX.
What are the key factors to evaluate for BIPSX?
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) currently holds an AI score of 47/100, indicating low score. Key strength: Leveraged exposure to the biotechnology sector.. Primary risk to monitor: Potential: Regulatory setbacks and clinical trial failures.. This is not financial advice.
How frequently does BIPSX data refresh on this page?
BIPSX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIPSX's recent stock price performance?
Recent price movement in ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Leveraged exposure to the biotechnology sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The fund's performance is highly dependent on the biotechnology sector.
- The fund's leveraged nature increases its volatility and risk.
- Investors should carefully consider their risk tolerance before investing in BIPSX.